ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
+$0.04 today
- Market cap
- $3.01B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
Volume 3.17M
Average 7.07M
ADMA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
ADMA Biologics, Inc.NASDAQ: ADMA
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow grows, but more slowly than its trailing trend
Q2 FY2026 free cash flow of $27.28M rose 45.8% year over year, behind the +77.1% change in trailing-twelve-month free cash flow. Sequentially, it fell 51.0% from the prior quarter.
Context
- Free cash flow amounted to 5.5% of revenue in FY2025, down 20.4 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +45.8% toward the trailing-twelve-month pace of +77.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 27.82M USD
- Year-over-year change
- -74.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.82M | -74.7% |
| FY2024 | 2024-12-31 | 110.1M | +2782.9% |
| FY2023 | 2023-12-31 | 3.82M | +105.2% |
| FY2022 | 2022-12-31 | (73.42M) | +41.7% |
| FY2021 | 2021-12-31 | (125.88M) | — |
Free Cash Flow vs competitors
How ADMA compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +77.1% is the highest of 4, against a peer median of -41.8%.
- Free cash flow amounts to 22.7% of revenue for ADMA, versus a peer median of 17.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €719.02M EUR | -11.4% | — | 9.7% | |
| LTM Jun 2026 | $116.47M USD | +77.1% | — | 22.7% | |
| LTM Mar 2026 | $79.46M USD | -43.9% | -35.9% | 142.2% | |
| LTM Mar 2026 | $34.36M USD | -41.8% | +3.4% | 17.9% | |
| Peer median (excluding ADMA) | — | -41.8% | -16.3% | 17.9% | |
Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.65M) | (65.9M) | (28.24M) | 197.67M | 146.93M |
| Depreciation & Amortization | 5.5M | 7.11M | 8.33M | 8.05M | 8.1M |
| Deferred Income Tax | 220.76K | 0 | 0 | (84.28M) | 11.02M |
| Stock-Based Compensation | 3.49M | 5.22M | 6.19M | 13.62M | 20.03M |
| Change in Working Capital | (51.68M) | (18.29M) | (10.12M) | (18.54M) | (139.6M) |
| Accounts Receivables | (15.34M) | 13.07M | (11.92M) | (22.58M) | (108.43M) |
| Inventory | (43.19M) | (38.56M) | (9.63M) | 2.67M | (36.23M) |
| Accounts Payables | 1.36M | 799.98K | 3.84M | 4.15M | 2.33M |
| Other Working Capital | 5.49M | 6.4M | 7.58M | (2.78M) | 2.74M |
| Other Non-Cash Items | 1.75M | 12.35M | 32.64M | 2.16M | 3.92M |
| Operating Cash Flow | (112.37M) | (59.51M) | 8.8M | 118.67M | 50.4M |
| Capital Expenditures | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (22.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (210K) | (349K) | (316K) |
| Investing Cash Flow | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (21.89M) |
| Debt Repayment | (34K) | 51.71M | (23.6M) | (60M) | (3.18M) |
| Common Stock Issued | 121.14M | 64.65M | 0 | 7.49M | 2.98M |
| Common Stock Repurchased | 0 | 0 | (1.42M) | 0 | (31.94M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (62K) | (7.51M) | (13.97M) | (5.8M) | (11.89M) |
| Financing Cash Flow | 121.05M | 108.85M | (38.99M) | (58.3M) | (44.02M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.83M) | 35.43M | (35.17M) | 51.8M | (15.52M) |
| Free Cash Flow | (125.88M) | (73.42M) | 3.82M | 110.1M | 27.82M |
ADMA Biologics, Inc.
NASDAQ:ADMA
Intrinsic Alpha fair value
Locked
Current Price
$13.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.